Cell based therapeutics in type 1 diabetes mellitus

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cell Therapy
• Immunology

Background:

• Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic beta-cell destruction.
• The pancreatic extracellular matrix (ECM) plays a role in T1DM pathogenesis and beta-cell function.
• Current T1DM treatments primarily focus on insulin replacement and glycemic control.

Purpose of the Study:

• To review the advancements in bioengineering, nanotechnology, and cell therapy for T1DM treatment.
• To explore the role of the pancreatic ECM in T1DM development and treatment strategies.
• To assess key enabling technologies for cell-based therapies in T1DM.

Main Methods:

• Review of recent scientific literature on T1DM, bioengineering, nanotechnology, and cell therapy.
• Analysis of surface engineering strategies and cell encapsulation techniques.
• Evaluation of therapeutic agent immobilization, oxygen-releasing systems, gene delivery, and bioimaging for T1DM.

Main Results:

• Surface engineering and advanced cell encapsulation techniques are crucial for cell-based T1DM therapies.
• Immobilization of therapeutic agents, oxygen release, gene delivery, and bioimaging enhance cell function and survival.
• Cell surface technologies enable control over cell interactions and provide

Conclusions:

• Bioengineering, nanotechnology, and cell therapy hold significant promise for T1DM treatment.
• Advanced cell surface technologies offer potential for immune camouflage and improved therapeutic efficacy.
• Future clinical trials are anticipated for these innovative cell-based T1DM treatments.